Lyme Disease Vaccine Market Forecast Reveals Where Future Industry Value Will Be Created
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Lyme Disease Vaccine Market Expected To Reach $1.57 Billion By 2030 At 7% CAGR
The lyme disease vaccine market has experienced robust expansion in recent years, with projections indicating an increase from $1.12 billion in 2025 to $1.2 billion in 2026, representing a compound annual growth rate (CAGR) of 7.3%. This historic growth was driven by a rising number of lyme disease cases in endemic areas, the recognized shortcomings of relying solely on antibiotics for treatment, early-phase vaccine development efforts, heightened public understanding of tick-borne illnesses, and enhanced disease monitoring through public health systems.
The market for Lyme disease vaccines is projected to experience robust expansion over the coming years, reaching a valuation of $1.57 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.0%. Several factors are fueling this anticipated growth during the forecast period, including the broadening of vaccination initiatives within high-risk regions, heightened funding allocated to combatting infectious diseases, the development of state-of-the-art vaccine technologies, a greater uptake of combination vaccines, and an intensified worldwide emphasis on the management of zoonotic diseases. Key developments shaping the industry during this timeframe encompass progress in recombinant vaccine platforms, a stronger push toward preventive immunization strategies, expanded clinical studies targeting tick-borne illnesses, a heightened focus on achieving durable immune responses, and enhanced partnerships between public health bodies and private sector organizations.
Download A Free Sample Report For Comprehensive Market Insights:
Lyme Disease Vaccine Market Demand Drivers: What Is Fueling Industry Growth?
The growing number of Lyme disease cases is anticipated to drive forward the expansion of the Lyme disease vaccine market. This illness, transmitted by ticks and caused by Borrelia bacteria, manifests with symptoms such as fever, tiredness, and skin rashes, and can result in severe complications affecting the joints, heart, or nervous system if left untreated. The rise in incidence is linked to climate change, with warmer temperatures and milder winters extending tick habitats and boosting human contact with infected ticks. These vaccines protect against the disease by teaching the immune system to identify and combat Borrelia bacteria, thereby lowering the infection risk. They make disease management easier by offering lasting immunity and enhancing public health results. To illustrate, as per the Centers for Disease Control and Prevention, a US federal health agency, in March 2025, around 89,000 Lyme disease cases were documented in the United States in 2023, though other estimation methods suggest that close to 476,000 individuals may receive a diagnosis and treatment for the disease each year. Consequently, the rising prevalence of Lyme disease is fueling the growth of the market for its vaccines.
The upward trend in healthcare spending is set to boost the advancement of the Lyme disease vaccine market going forward. Healthcare expenditure encompasses all funds allocated to medical care, therapies, facilities, research, and public health programs aimed at sustaining or enhancing health. This spending increase is driven by the growing occurrence of chronic conditions that demand extended and expensive care. Higher healthcare costs benefit Lyme disease vaccine development by channeling more resources into research and clinical trials, which speeds up innovation and manufacturing. They also enable better vaccine technologies, improving availability and efficacy for groups at risk. For instance, the Office for National Statistics, a UK government agency, reported in May 2024 that total healthcare expenditure grew by 5.6% in nominal terms in 2023, marking a 0.9% increase compared to 2022. Thus, the rise in healthcare expenditure is propelling the growth of the Lyme disease vaccine market.
Lyme Disease Vaccine Market Segment Performance And Strategic Opportunities
The lyme disease vaccine market covered in this report is segmented –
1) By Vaccine Type: Recombinant Vaccines, Subunit Vaccines, Live Attenuated Vaccines, Other Vaccine Types
2) By Technology: Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Nucleic Acid Test, Serological Test
3) By Age Group: Pediatric, Adult, Geriatric
4) By Distribution Channel: Hospitals And Clinics, Pharmacies, Government Supply, Other Distribution Channels
5) By End User: Hospitals, Clinical Laboratories, Other End Users
Subsegments:
1) By Recombinant Vaccines: Protein-Based Recombinant Vaccines, Vector-Based Recombinant Vaccines, Deoxyribonucleic Acid (DNA)-Based Recombinant Vaccines
2) By Subunit Vaccines: Protein Subunit Vaccines, Polysaccharide Subunit Vaccines, Conjugate Subunit Vaccines
3) By Live Attenuated Vaccines: Naturally Attenuated Vaccines, Genetically Attenuated Vaccines, Temperature-Sensitive Attenuated Vaccines
4) By Other Vaccine Types: Toxoid Vaccines, Inactivated Vaccines, Vectored Vaccines
Lyme Disease Vaccine Market Innovation Trends: Which Developments Are Transforming The Industry?
Key players in the Lyme disease vaccine sector are concentrating on advancing their late-stage pipeline products, including booster vaccines, with the goal of addressing unmet medical needs, improving immune responses, and streamlining immunization schedules. Booster vaccines refer to additional doses administered after the primary series to restore or boost long-term immunity. A case in point is Valneva SE, a biotechnology firm headquartered in France, which in September 2025 announced positive immunogenicity and safety findings from its ongoing Phase 2 study of its Lyme disease vaccine candidate, VLA15. This multivalent vaccine is designed to prime the immune system to generate antibodies targeting OspA proteins present on Borrelia bacteria. When an infected tick bites, these antibodies neutralize the bacteria within the tick, thus preventing transmission to humans. The robust immune reaction and favorable safety profile observed after a third booster dose were aligned with results from earlier annual boosters, reinforcing alignment with the expected advantages of a yearly vaccination regimen prior to each Lyme season. This booster approach is designed to ensure ongoing protection against Lyme disease, highlighting the possibility of an annual pre-season booster that simplifies prevention for individuals at risk.
Lyme Disease Vaccine Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the lyme disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Boehringer Ingelheim GmbH, University of Pennsylvania, Elanco Animal Health Incorporated, Zoetis Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Aegis Life Inc., Bioveta a.s., Dynavax Technologies Corporation, Valneva SE, MassBiologics of UMass Chan Medical School, Inovio Pharmaceuticals Inc., US Biologic Inc., Blue Lake Biotechnology Inc.
Access The Complete Lyme Disease Vaccine Market Report:
Lyme Disease Vaccine Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the Lyme disease vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
